stockrow
Monday 9 November 2026
Export KROS’s income statement to Excel — free account
Keros Therapeutics, Inc.
KROSKeros Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $244.1 million, up 6,775.0% from fiscal 2024.
- Revenue
- +120.2%
- EPS
- +494.4%
- Free cash flow
- +6.87%
Quarter to September 2026, against a year earlier
9.36
0.09
−0.95%
Follow KROS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | 10 | 10 | — | 20 | — | 0 | 4 | 244 | 55 | +57.8% | 16 | 14 | 45 | (43.2%) | |
| Gross margin, % | — | — | 0.00 | 100.00 | 0.00 | 100.00 | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | +100.0 pt | ||||||
| EBT | — | — | (1) | (12) | (46) | (57) | (105) | (153) | (187) | 92 | (62) | n/m | ||||||
| EBT margin, % | — | — | (10.78) | (123.36) | 0.00 | (282.25) | 0.00 | (101,319.21) | (5,269.10) | 37.65 | (113.53) | +48.4 pt | ||||||
| Net income | — | 0 | (1) | (12) | (45) | (59) | (105) | (153) | (187) | 87 | (62) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.53 | 4.30 | 0.00 | 0.86 | 0.00 | 0.01 | 0.09 | 6.56 | 2.77 | +43.3% | |||||
| Earnings | — | — | (0.12) | (6.08) | (2.93) | (2.52) | (4.15) | (5.20) | (5.00) | 2.34 | (2.81) | n/m | ||||||
| Cash flow | — | — | 0.37 | (6.87) | (2.38) | (2.66) | (2.78) | (4.23) | (4.30) | 2.89 | (2.41) | +34.0% | ||||||
| Capex | — | — | 0.00 | (0.12) | (0.02) | (0.04) | (0.05) | (0.08) | (0.05) | (0.04) | (0.02) | n/m | ||||||
| Free cash flow | — | — | 0.37 | (6.99) | (2.40) | (2.71) | (2.82) | (4.31) | (4.35) | 2.85 | (2.43) | +33.7% | ||||||
| Book value | — | — | (0.38) | 0.21 | 16.88 | 10.42 | 10.99 | 11.28 | 15.27 | 8.14 | 14.03 | n/m | ||||||
| Shares, m | — | — | 19 | 2 | 16 | 23 | 25 | 29 | 37 | 37 | 24 | +10.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 10.95 | 0.00 | 1.8 | |||||
| P/S | — | — | 4.99 | 4.99 | — | 54.39 | — | 62.72 | 166.94 | 3.11 | 3.38 | 49.5 | ||||||
| P/B | — | — | 0.00 | 0.00 | — | 5.61 | — | 3.82 | 1.04 | 2.50 | 0.67 | 2.2 | ||||||
| EV/Sales | — | — | (0.46) | (0.46) | — | 45.23 | — | 46.36 | 9.21 | 1.93 | (1.33) | 17.0 | ||||||
| EV/FCF | — | — | 0.21 | 0.21 | — | (17.97) | — | (7.39) | (0.20) | 4.44 | 1.52 | (3.5) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | 7 | (16) | (37) | (62) | (70) | (125) | (161) | 108 | (48) | +47.6% | |||||
| Capex | — | — | 0 | 0 | 0 | (1) | (1) | (2) | (2) | (2) | 0 | +32.4% | ||||||
| Free cash flow | — | — | 7 | (16) | (37) | (63) | (71) | (127) | (163) | 106 | (48) | +47.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 14 | 4 | 261 | 240 | 269 | 323 | 561 | 295 | 272 | +54.5% | |||||
| Net debt | — | — | 0 | (7) | (266) | (230) | (279) | (331) | (560) | (287) | (259) | +197.9% | ||||||
| Shareholders’ equity | — | — | (7) | 0 | 262 | 243 | 277 | 332 | 572 | 303 | 279 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (17.12) | (73.69) | (32.35) | (22.39) | (37.25) | (45.21) | (38.01) | 18.24 | (11.76) | +35.4 pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | (268.30) | 0.00 | (9,963.71) | (1,133.80) | 268.69 | (233.22) | +268.7 pt | ||||||
| ROE | — | — | 17.62 | 106.17 | (37.45) | (23.27) | (40.21) | (50.19) | (41.46) | 19.90 | (12.56) | +2.3 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 23 | 35 | 60 | 105 | 136 | 169 | 78 | — | +22.6% | |||||
| Revenue/emp, $m | — | — | 0.00 | 0.43 | 0.00 | 0.34 | 0.00 | 0.00 | 0.02 | 3.13 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026
Keros Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PYXS Pyxis Oncology, Inc. | $198.6M | — (loss-making) | — (loss-making) | — | n/m | −5.46% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| IFRX InflaRx N.V. | $192.3M | — (loss-making) | — (loss-making) | −128.93% (below 0%: shrinking) | n/m | +59.76% (above 0%: growing) | 14,029.95% | 0.00% | Compare |
| TRDA Entrada Therapeutics, Inc. | $191.5M | — (loss-making) | — (loss-making) | −43.93% (below 0%: shrinking) | n/m | −7.05% (below 0%: shrinking) | 100.00% | (4,606.52%) | Compare |
| PRQR ProQR Therapeutics N.V. | $190.5M | — (loss-making) | — (loss-making) | +135.03% (above 0%: growing) | n/m | −1.06% (below 0%: shrinking) | 100.00% | (100.72%) | Compare |
| RNA Atrium Therapeutics, Inc. | $185.8M | — (loss-making) | — (loss-making) | — | n/m | — | 100.00% | (752.93%) | Compare |
| CGEN Compugen Ltd. | $185.7M | 5.2× | — (loss-making) | +107.00% (above 0%: growing) | n/m | −155.42% (below 0%: shrinking) | (3.54%) | (339.62%) | Compare |
| KROS Keros Therapeutics, Inc. | $183.7M | — (loss-making) | — (loss-making) | +120.22% (above 0%: growing) | n/m | +6.87% (above 0%: growing) | 100.00% | 32.04% | |
| BCYC Bicycle Therapeutics PLC Sponsored ADR | $182.5M | — (loss-making) | — (loss-making) | +190.24% (above 0%: growing) | n/m | +43.48% (above 0%: growing) | 100.00% | (39.57%) | Compare |
| ACOG Alpha Cognition Inc. | $180.5M | — (loss-making) | — (loss-making) | +267.56% (above 0%: growing) | n/m | −109.25% (below 0%: shrinking) | 94.80% | (127.29%) | Compare |
| Median of peers | $188.1M | — | — | +121.02% | — | −5.46% | 100.00% | (114.00%) |
Pay and ownership Proxy statement filed 22 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 2.54m | 3.71m | 28.86 |
| 2024 | 6.27m | 2.70m | 22.44 |
| 2023 | 8.93m | 3.44m | 56.37 |
Ownership
Directors and executive officers, together
12.60%
BlackRock, Inc.
10.10%
Jasbir Seehra, Ph.D.
8.80%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement